Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Henagliflozin - Jiangsu HengRui Medicine

Next Previous
Drug Profile

Henagliflozin - Jiangsu HengRui Medicine

Alternative Names: Henggliflozin Tablets - Jinagsu Hengrui Meidicine; Proline Henggliflozin Tablets - Jiangsu HengRui Medicine; Ruiqin; SHR-3824

Latest Information Update: 16 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Chlorobenzenes; Ethers; Fluorobenzenes; Glucosides; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase II Renal failure

Most Recent Events

  • 24 Jun 2025 Shandong Suncadia Medicine completes a phase II trial in Renal failure (Treatment-experienced) in China (PO) (NCT06221059) (Jiangsu Hengrui Medicine pipeline, July 2026
  • 10 Jan 2025 Launched for Type 2 diabetes mellitus (Combination therapy) in China (PO) (Jiangsu Hengrui Medicine Co pipeline; January 2025)
  • 02 Mar 2024 Phase-II clinical trials in Renal failure (Treatment-experienced) in China (PO) (NCT06221059) (Jiangsu Hengrui Medicine pipeline, July 2026

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top